A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Summary

The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.

Timeline

Start

2021-06-01

Primary completion

2024-05-09

Completion

2024-05-09

Drugs

Indications